anemia%20-%20iron-deficiency
ANEMIA - IRON-DEFICIENCY
Anemia is a condition wherein the blood has low levels of red blood cells (RBC), hemoglobin (oxygen-carrying pigment in whole blood) and/or hematocrit (intact RBC in blood) making it insufficient to address the physiologic needs of the body.
Iron-deficiency anemia is the anemia that resulted from inadequate iron supplementation or excessive blood loss.
It is the most common nutritional disorder worldwide and accounts for more than half of anemia cases.
It is prevalent among preschool children and pregnant women.

Monitoring

  • Correction of iron-deficiency anemia usually occurs within 2-4 months of appropriate therapy
  • There are no standard recommendations for follow-up after starting iron therapy
    • But it is advised to have CBC monthly for 3 months and then every 3 months for 1 year
    • Response to iron therapy is expected after 2-3 weeks of treatment, and may be seen as reticulocytosis in 4 days and hemoglobin >10 g/L in 4 weeks
    • If there is no favorable response, it may mean non-compliance, continued blood loss with inadequate iron replacement, malabsorption, wrong diagnosis or other complicating factors, eg H pylori infection; thus further investigation and reassessment of treatment is advised
    • If hemoglobin and RBC indices remain normal, one additional CBC should be obtained 12 months later
  • Further follow-ups are not necessary if the patient is asymptomatic and the hematocrit level is normal
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving 2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.